Latest Breaking News On - Armata pharmaceuticals - Page 11 : comparemela.com

Armata Pharmaceuticals, Inc (NYSEAMERICAN:ARMP) Sees Large Growth in Short Interest

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Rating) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 34,900 shares, a growth of 52.4% from the February 28th total of 22,900 shares. Based on an average trading volume of 21,800 shares, the short-interest ratio is presently 1.6 days. […]

Los angelesArmata pharmaceuticalsRenaissance technologiesArmata pharmaceuticals incNorthern trust corpInstitutional trading of armata pharmaceuticalsNews ratings for armata pharmaceuticals dailyArmata pharmaceuticals stock performanceVanguard group incGet ratingStreet groupTrust corpVanguard groupArmata pharmaceuticals dailyNyseamerican armp

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesBrian varnumJoyce allairePierre kymeUs department of defenseLifesci advisorsDefense health agencyArmata pharmaceuticals incWarfighter medical research programInnoviva incInnoviva strategic opportunitiesTechnology enterprise consortiumPrnewswire armata pharmaceuticals incRecent developmentsChief executive officerMedical technology enterprise consortium

Phage cocktail, AP-PA02, may safely treat Pseudomonas aeruginosa infection | Early CF trial reports safety, potential efficacy

The phage therapy was well tolerated and eased Pseudomonas aeruginosa airway load in treated trial patients, Phase 2b CF study proposed.

Brian varnumMina pastagiaArmata pharmaceuticals

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P a Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesMina pastagiaBrian varnumJoyce allairePierre kymeLifesci advisorsArmata pharmaceuticals incPrnewswire armata pharmaceuticals incNon cystic fibrosis bronchiectasisChief medical officerChief executive officerArmata pharmaceuticalsAnnual reportSci advisors

Amarin Urges Shareholders to Vote Against Sarissa s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE

Amarin Urges Shareholders to Vote Against Sarissa s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyMark marmurLisa defrancescoWilkinson brimmer katcherJoele frankSarissa misguided campaign to remove amarinIronwood pharmaceuticals incAegerion pharmaceuticals incVivus incRopes grayGlass lewis coPharmaceuticals incAlkermes plcEmmaus life sciences incNovelion therapeutics inc